anti-CCP antibody
Selected indexed studies
- Anti-CCP biosensors in rheumatoid arthritis. (Clin Chim Acta, 2024) [PMID:38857671]
- Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. (RMD Open, 2024) [PMID:38942592]
- Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. (Front Immunol, 2021) [PMID:34054878]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Anti-CCP biosensors in rheumatoid arthritis. (2024) pubmed
- Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. (2024) pubmed
- Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. (2021) pubmed
- The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19. (2024) pubmed
- Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. (2022) pubmed
- Validation of Analytical Performance and Diagnostic Effectiveness of Anti-CCP Antibody Based on the Light-Initiated Chemiluminescence Assay. (2024) pubmed
- Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors. (2025) pubmed
- Correlation between high-frequency ultrasonography of patients with early rheumatoid arthritis and anti-CCP antibody. (2019) pubmed
- Helicobacter pylori upregulates PAD4 expression via stabilising HIF-1α to exacerbate rheumatoid arthritis. (2024) pubmed
- Large-scale multicenter study reveals anticitrullinated SR-A peptide antibody as a biomarker and exacerbator for rheumatoid arthritis. (2025) pubmed